Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vision tests could speed up AMD treatment trials

NCT ID NCT07515521

Knowledge-focused Sponsor: Maximilian Pfau Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing new eye exams to see if they can better track early age-related macular degeneration (AMD). Researchers will measure how quickly the eye adapts to darkness in 150 healthy volunteers and people with early AMD. The goal is to find reliable ways to measure disease progression, which could help design future treatment trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide better ways to measure early AMD progression, enabling more effective treatment trials in the future.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly help patients. The tests may not prove sensitive enough to track disease changes over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers and patients with early or intermediate AMD.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent. * All biological sexes and gender identities. * Age \&gt;=18 years for healthy volunteers; age \&gt;=55 years for participants with AMD. * Ability to understand German or English sufficiently for study information and procedures. Additional Inclusion Criteria by Cohort: Healthy Volunteers: \- No drusen \>63 um and no subretinal drusenoid deposits in either eye. Early AMD: \- Study eye with drusen \>63 um but \<125 um and no pigmentary changes. Intermediate AMD: \- Study eye with drusen \>125 um and/or pigmentary changes. Exclusion Criteria: * Claustrophobia relevant to dark-adaptation procedures. * Hypersensitivity to indocyanine green or sodium iodide, iodine allergy, or hyperthyroidism. * Known pregnancy. * Study eye history of ocular surgery other than cataract surgery, YAG capsulotomy, or laser retinopexy. * Ocular disease in the study eye that could affect visual function testing in the opinion of the investigators. * Medical conditions or planned operations that could interfere with follow-up. * Inability to comply with study procedures or insufficient language skills in the study language. * Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration (AMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration (AMD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Ophthalmology, University Hospital Bonn

    RECRUITING

    Bonn, 53127, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.